Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 6 de 6
Filter
1.
J Alzheimers Dis ; 73(1): 77-86, 2020.
Article in English | MEDLINE | ID: mdl-31743997

ABSTRACT

BACKGROUND: Existing literature on factors associated with supportive care service (SCS) use is limited. A better understanding of these factors could help tailor SCS to the needs of frequent users, as well as facilitate targeted outreach to populations that underutilize available services. OBJECTIVE: To investigate the prevalence of SCS use and to identify factors associated with, and barriers to, service use. METHODS: California Alzheimer's Disease Center patients with AD (n = 220) participated in the study from 2006-2009. Patients and their caregivers completed assessments to determine SCS use. Cognitive, functional, and behavioral status of the patients were also assessed. A two-part hurdle analysis identified 1) factors associated with any service use and 2) service use frequency among users. RESULTS: Forty percent of participants reported using at least one SCS. Patients with more impaired cognition and activities of daily living and more of the following: total number of medications, comorbid medical conditions, and years of education were more likely to use any SCS (p < 0.05). Factors associated with more frequent SCS use included younger age, more years of education, older age of AD onset, female gender, and having a spouse or relative for a caregiver (p < 0.05). Caregivers frequently indicated insufficient time as a reason for not receiving enough services. CONCLUSION: Factors associated with any SCS use mostly differed from those associated with SCS frequency, suggesting different characteristics between those who initiate versus those who continue SCS use. Our findings highlight the importance of targeted education on services and identifying barriers to long-term SCS use.


Subject(s)
Alzheimer Disease/therapy , Caregivers/psychology , Activities of Daily Living , Age Factors , Age of Onset , Aged , Aged, 80 and over , Alzheimer Disease/psychology , California , Comorbidity , Educational Status , Female , Health Services , Humans , Male , Mental Status and Dementia Tests , Quality of Life , Social Support , Socioeconomic Factors
2.
Alzheimers Dement ; 7(3): e51-9, 2011 May.
Article in English | MEDLINE | ID: mdl-21546322

ABSTRACT

BACKGROUND: Frequent review and update of guidelines are necessary for them to remain current and useful for clinical practices. This second revision of the postdiagnostic management of Alzheimer's disease (AD) guideline by the California Workgroup was prompted by significant advances in knowledge about appropriate care management, including pharmacologic and nonpharmacologic approaches to treatment of the disease, accompanying behavioral problems, and functional decline. The focus remains explicitly on primary care, where the majority of it occurs for those with AD and other dementias. METHODS: In all, 40 experts in dementia care were recruited from a variety of disciplines across California. Four workgroups were created that reviewed recent research findings from a total of 569 publications since 2002. The revised Guideline incorporates 305 new references, including 11 state and federal laws, in addition to 78 references from the previous version. RESULTS: The Guideline is divided into four sections that address postdiagnostic management: (1) assessment, (2) treatment, (3) patient and family education and support, and (4) legal considerations associated with AD. Significant revisions and changes in each area and the underlying research to support the recommendations are presented in this article. New topics related to early stage and end-of-life were identified and recommendations were developed for these specific populations. CONCLUSIONS: The Guideline recommendations provide a framework to inform and improve medical care for AD by primary health care providers.


Subject(s)
Alzheimer Disease/diagnosis , Alzheimer Disease/therapy , Social Support , Alzheimer Disease/psychology , California , Humans , Primary Health Care/legislation & jurisprudence , Primary Health Care/standards
3.
Am J Geriatr Psychiatry ; 16(6): 469-77, 2008 Jun.
Article in English | MEDLINE | ID: mdl-18515691

ABSTRACT

OBJECTIVE: To compare the rates of depression in Alzheimer Disease (AD) determined using National Institute of Mental Health (NIMH) provisional criteria for depression in AD (NIMH-dAD) to those determined using other established depression assessment tools. DESIGN: Descriptive longitudinal cohort study. SETTING: The Alzheimer's Disease Research Centers of California. PARTICIPANTS: A cohort of 101 patients meeting NINDS-ADRDA criteria for possible/probable AD, intentionally selected to increase the frequency of depression at baseline. MEASUREMENTS: Depression was diagnosed at baseline and after 3 months using NIMH-dAD criteria and the Structured Clinical Interview for Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition (DSM-IV) Axis I Disorders. Depressive symptoms also were assessed with the Cornell Scale for Depression in Dementia (CSDD), the Geriatric Depression Scale (GDS), and the Neuropsychiatric Inventory Questionnaire. RESULTS: The baseline frequency of depression using NIMH-dAD criteria (44%) was higher than that obtained using DSM-IV criteria for major depression (14%; Z = -5.50, df = 101, p <0.001) and major or minor depression (36%; Z = -2.86, df = 101, p = 0.021) or using established cut-offs for the CSDD (30%; Z = -2.86, df = 101, p = 0.004) or GDS (33%; Z = -2.04, df = 101, p = 0.041). The NIMH-dAD criteria correctly identified all patients meeting DSM-IV criteria for major depression, and correlated well with DSM-IV criteria for major or minor depression (kappa = 0.753, p <0.001), exhibiting 94% sensitivity and 85% specificity. The higher rates of depression found with NIMH-dAD criteria derived primarily from its less stringent requirements for the frequency and duration of symptoms. Remission rates at 3 months were similar across instruments. CONCLUSIONS: The NIMH-dAD criteria identify a greater proportion of AD patients as depressed than several other established tools.


Subject(s)
Alzheimer Disease/diagnosis , Depressive Disorder, Major/diagnosis , Depressive Disorder/diagnosis , Aged , Aged, 80 and over , Alzheimer Disease/epidemiology , Alzheimer Disease/psychology , Cohort Studies , Comorbidity , Cross-Sectional Studies , Depressive Disorder/epidemiology , Depressive Disorder/psychology , Depressive Disorder, Major/epidemiology , Depressive Disorder, Major/psychology , Diagnostic and Statistical Manual of Mental Disorders , Female , Follow-Up Studies , Humans , Incidence , Longitudinal Studies , Male , Mental Status Schedule/statistics & numerical data , Neuropsychological Tests/statistics & numerical data , Personality Assessment/statistics & numerical data , Psychometrics/statistics & numerical data , Reproducibility of Results
4.
Maturitas ; 45(2): 83-8, 2003 Jun 30.
Article in English | MEDLINE | ID: mdl-12787966

ABSTRACT

OBJECTIVE: To examine the relationship between estrogen replacement therapy (ERT) and frontotemporal dementia (FTD). METHODS: We examined the files of thirty female patients diagnosed with FTD at the University of California, San Francisco (UCSF)-Alzheimer's Disease Research Center in Fresno between the years of 1994 and 1999. Twenty-one patients (70%) were found to have been taking ERT at the time of their evaluation. This was compared with an estimate of estrogen use in a similar cohort from the general population (24%). RESULTS: Chi-square (chi(2)) analysis found this number to be significantly greater than estimates from the general population significant (chi(2)[df=1, N=30]=34.803, P<0.01). CONCLUSIONS: Three potential explanations for the findings are put forth, including an intriguing neurobiological relationship between estradiol and tau, the complex protein implicated in the etiology of FTD.


Subject(s)
Dementia/epidemiology , Dementia/prevention & control , Estrogen Replacement Therapy/statistics & numerical data , Aged , California/epidemiology , Case-Control Studies , Dementia/etiology , Dementia/pathology , Female , Humans , Middle Aged
5.
Am Fam Physician ; 65(11): 2263-72, 2002 Jun 01.
Article in English | MEDLINE | ID: mdl-12074525

ABSTRACT

Family physicians play a key role in assessing and managing patients with Alzheimer's disease and in linking the families of these patients to supportive services within the community. As part of comprehensive management, the family physician may be responsible for coordinating assessments of patient function, cognition, comorbid medical conditions, disorders of mood and emotion, and caregiver status. Suggestions for easily administered and scored assessment tools are provided, and practical tips are given for supporting primary caregivers, thereby increasing efficiency and quality of care for patients with Alzheimer's disease.


Subject(s)
Alzheimer Disease/diagnosis , Geriatric Assessment , Activities of Daily Living , Aged , Alzheimer Disease/physiopathology , Caregivers/psychology , Cognition , Comorbidity , Family Practice , Guidelines as Topic , Humans , Mood Disorders/complications , Mood Disorders/diagnosis , Neuropsychological Tests
6.
Am Fam Physician ; 65(12): 2525-34, 2002 Jun 15.
Article in English | MEDLINE | ID: mdl-12086242

ABSTRACT

Once the clinical diagnosis of Alzheimer's disease has been made, a treatment plan must be developed. This plan should include cholinesterase inhibitor therapy to temporarily improve cognition or slow the rate of cognitive decline, management of comorbid conditions, treatment of behavioral symptoms and mood disorders, provision of support and resources for patient and caregiver, and compliance with state-mandated reporting requirements for driving impairment and elder abuse. The primary caregiver can be a valuable ally in communication, management of care, and implementation of the care plan. Patient symptoms and care needs change as Alzheimer's disease progresses. In the early stage of the disease, the family physician should discuss realistic expectations for drug therapy, solicit patient and family preferences on future care choices, and assist with advance planning for future care challenges. In the middle stage, the patient may exhibit behavioral symptoms that upset the caregiver and are difficult to manage. When the patient is in the advanced stage of Alzheimer's disease, the caregiver may need support to provide for activities of daily living, help in making a difficult placement decision, and guidance in considering terminal care options. Throughout the course of the disease, routine use of community resources allows care to be provided by a network of professionals, many of whom will be specialists in Alzheimer's disease.


Subject(s)
Alzheimer Disease/drug therapy , Cholinesterase Inhibitors/therapeutic use , Indans/therapeutic use , Phenylcarbamates , Piperidines/therapeutic use , Advance Directives , Alzheimer Disease/complications , Carbamates/therapeutic use , Disease Progression , Donepezil , Humans , Lorazepam/therapeutic use , Patient Education as Topic , Risperidone/therapeutic use , Rivastigmine
SELECTION OF CITATIONS
SEARCH DETAIL
...